Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.81 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.81 |
| ▸ | BMP1 | P13497 | 9/20 | 0.80 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.65 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.59 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 4/20 | 0.58 |
| ▸ | MMP2 | P08253 | 3/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348080 | 1.00 | KEAP1 (0.81) | KEAP1NFE2L2BMP1TAS2R14PTGES | |
| SCHEMBL7341410 | 0.90 | KEAP1 (0.67) | KEAP1NFE2L2BMP1TAS2R14PTGES | |
| SCHEMBL7341408 | 0.90 | KEAP1 (0.67) | KEAP1NFE2L2BMP1TAS2R14PTGES | |
| SCHEMBL22251959 | 0.90 | KEAP1 (1.00) | KEAP1NFE2L2BMP1MMP9MMP2 | |
| SCHEMBL22251983 | 0.90 | KEAP1 (1.00) | KEAP1NFE2L2BMP1MMP9MMP2 | |
| SCHEMBL7348032 | 0.88 | BMP1 (0.80) | KEAP1NFE2L2BMP1MMP9MMP2 | |
| SCHEMBL7344309 | 0.88 | BMP1 (0.80) | KEAP1NFE2L2BMP1MMP9MMP2 | |
| SCHEMBL7091056 | 0.88 | MMP2 (0.76) | KEAP1NFE2L2BMP1TAS2R14PTGES | |
| SCHEMBL7091051 | 0.88 | MMP2 (0.76) | KEAP1NFE2L2BMP1TAS2R14PTGES | |
| SCHEMBL7091054 | 0.88 | MMP2 (0.76) | KEAP1NFE2L2BMP1TAS2R14PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |